CAS: 119567-79-2 - Viramidine
Formula:C8H13N5O4
InChI:InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1
InChI key:InChIKey=NHKZSTHOYNWEEZ-AFCXAGJDSA-N
SMILES:N=C(N)C=1N=CN(N1)C2OC(CO)C(O)C2O
- Synonyms:
- 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboximidamide
- 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine
- 1-β-<span class="text-smallcaps">D</span>-Ribofuranosyl-1H-1,2,4-triazole-3-carboximidamide
- 1H-1,2,4-Triazole-3-carboximidamide, 1-beta-D-ribofuranosyl-
- 1H-1,2,4-Triazole-3-carboximidamide, 1-β-<span class="text-smallcaps">D</span>-ribofuranosyl-
- Icn 3142
- Ribamidine
- Ribavirin amidine
- Unii-R3B1994K2E
- Viramidine
- See more synonyms
- Taribavirin
- 1-β-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboximidamide
- 1H-1,2,4-Triazole-3-carboximidamide, 1-β-D-ribofuranosyl-
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
1H-1,2,4-Triazole-3-carboximidamide, 1-β-D-ribofuranosyl- REF: IN-DA0010OOCAS: 119567-79-2 | - - - | To inquire | Thu 12 Dec 24 | |
Viramidine REF: 3D-AV178051CAS: 119567-79-2 | Min. 95% | To inquire | Mon 23 Dec 24 | |
Taribavirin REF: TM-T16993CAS: 119567-79-2 | 98% | 907.00 €~2,337.00 € | Thu 30 Jan 25 |
1H-1,2,4-Triazole-3-carboximidamide, 1-β-D-ribofuranosyl-
CAS:119567-79-2
Formula:
C8H13N5O4
Molecular weight:
243.2199
Ref: IN-DA0010OO
Undefined size | To inquire |
Estimated delivery in United States, on Thursday 12 Dec 2024
Viramidine
CAS:119567-79-2
Viramidine is an oral prodrug that is converted to the active compound, viramidine monophosphate, in …
Purity:
Min. 95%
Ref: 3D-AV178051
Undefined size | To inquire |
Estimated delivery in United States, on Monday 23 Dec 2024
Taribavirin
CAS:119567-79-2
Taribavirin: oral drug targeting HCV in liver, spares RBCs to reduce risk of anemia.
Formula:
C8H13N5O4
Purity:
98%
Color and Shape:
Solid
Molecular weight:
243.22
Ref: TM-T16993
25mg | 1,410.00 € | ||
50mg | 1,851.00 € | ||
100mg | 2,337.00 € |
Estimated delivery in United States, on Thursday 30 Jan 2025